CC
BHC icon

Cypress Capital’s Bausch Health BHC Stock Holding History

Cypress Capital’s Portfolio BHC Stock Details BHC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18,507
Closed -$155K – 102
2022
Q2 		$155K Hold
18,507
– – 0.02% 173
2022
Q1 		$423K Sell
18,507
-1,950
-10% -$47.7K 0.05% 155
2021
Q4 		$565K Hold
20,457
– – 0.06% 142
2021
Q3 		$570K Buy
+20,457
New +$580K 0.07% 131

Other funds holding BHC

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Cypress Capital's BHC Position: Q3 2022 in Review

Cypress Capital sold out of Bausch Health (BHC) in Q3 2022, closing a stake of 18,507 shares — an estimated $155K sold.

Cypress Capital first reported a position in BHC in Q3 2021 and held it in 4 quarters. The position peaked at $570K in Q3 2021. 283 funds tracked by Wall St. Rank hold BHC as of Q3 2022.

  • Cypress Capital reported no remaining Bausch Health position as of Q3 2022 after selling out during the quarter.
  • Cypress Capital sold 18,507 Bausch Health shares in Q3 2022, an estimated $155K.
  • Cypress Capital first reported a position in Bausch Health in Q3 2021 and held it in 4 quarters.
  • Cypress Capital's Bausch Health position peaked at $570K in Q3 2021.
  • 283 funds tracked by Wall St. Rank held Bausch Health as of Q3 2022.

Based on Cypress Capital's 13F filing for Q3 2022, filed 1 Feb 2023.